IMPACT BIOMEDICAL INC. (IBO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45259L2051
IMPACT BIOMEDICAL INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 32,000.00 USD |
| Gross profit | -392,000.00 USD |
| Operating income | -4.28 m USD |
| EBIT | -13.66 m USD |
| Net income | -11.84 m USD |
| Diluted EPS – continuing operations | -0.38 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IMPACT BIOMEDICAL INC.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc
More stocks
- Grove Collaborative Holdings, Inc. (GROV)
- NEUROPHET, Inc. (380550.KQ)
- Cj Seafood (011150.KS)
- SAGA COMMUNICATIONS INC (SGA)
- Osang Healthcare Co.,Ltd (036220.KQ)
- Sugentech Inc (253840.KQ)
- READING INTERNATIONAL INC (RDI)
- Sinsin Pharmaceutical Co. Ltd (002800.KQ)
- Semi Total Solution Inc. (0017J0.KQ)
- Noble Development Public Company Limited (NOBLE.BK)
- Renalytix plc (RENXF)
- Synic Solution Co., Ltd. (234030.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.